PROLIA®

Why Practitioners Choose PROLIA®

PROLIA® is administered as a 60mg injection every six months, offering an alternative to the weekly or monthly schedules required with many oral bisphosphonates. It also avoids fasting and post-dose positioning requirements, while gastrointestinal tolerability is generally less of a practical concern. For clinics, each six-month visit provides a natural opportunity to review treatment, assess supplementation, check relevant laboratory results, and plan follow-up care.[1][6] Denosumab does not require dose adjustment in renal impairment, which may make it an option when reduced kidney function limits the use of bisphosphonates.

Contact Med Supply Solutions About PROLIA®

Licensed healthcare professionals may contact the Med Supply Solutions support team for general information about PROLIA®, including product details, sourcing considerations, and documentation inquiries.

What Is PROLIA® Used For?

PROLIA® is indicated for postmenopausal women with osteoporosis at high risk for fracture and for increasing bone mass in men with osteoporosis at high risk for fracture. Additional approved indications include glucocorticoid-induced osteoporosis in men and women at high risk, bone loss in men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, and bone loss in women receiving adjuvant aromatase-inhibitor therapy for breast cancer. [1] Denosumab is a human IgG2 monoclonal antibody that targets RANKL and blocks its interaction with the RANK receptor on osteoclasts and their precursor cells. Interrupting this pathway limits osteoclast development, activity, and survival, which reduces bone resorption and helps increase bone mineral density.[1][4] In the pivotal FREEDOM trial, denosumab administered every six months significantly lowered the risk of vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis over a 36-month period.[3]

PROLIA® Dosing & Administration

• Administer PROLIA® 60mg as a single subcutaneous injection every six months into the upper arm, upper thigh, or abdomen; a healthcare professional should perform administration.
• Patients should receive adequate calcium and vitamin D supplementation — the FDA label specifies 1,000mg calcium daily and at least 400 IU vitamin D daily.
• Store at 2°C–8°C in the original carton; do not freeze. Once removed from refrigeration, PROLIA® may be stored at up to 25°C for a maximum of 14 days. Patients receiving XGEVA® must not receive PROLIA®, as both contain denosumab. [1]

PROLIA® Safety Profile

Boxed Warning: Severe Hypocalcemia in Advanced CKD

PROLIA® carries an FDA Boxed Warning for severe hypocalcemia in patients with advanced chronic kidney disease, including those receiving dialysis. Reported complications have included hospitalization, life-threatening events, and death, with the risk particularly elevated in patients who also have CKD-mineral and bone disorder. Before treatment begins, existing hypocalcemia should be corrected, and patients with advanced CKD should be evaluated for CKD-MBD. Current labeling also calls for frequent calcium monitoring in this population, especially during the first 2 to 10 weeks after each injection.[1][5]

Discontinuation and Rebound Vertebral-Fracture Risk

PROLIA® should not be stopped, skipped, or substantially delayed without a transition plan. Discontinuation is associated with rapid rebound in bone turnover, loss of bone mineral density, and an increased risk of multiple vertebral fractures — new vertebral fractures have been reported as early as seven months after the last injection. When treatment is discontinued, patients must transition to another antiresorptive therapy. [1][4] Other clinically important risks include serious hypersensitivity reactions, osteonecrosis of the jaw, atypical femoral fractures, serious infections including cellulitis, dermatologic reactions, and severe musculoskeletal pain. Common adverse reactions vary by indication and may include back pain, extremity pain, musculoskeletal pain, hypercholesterolemia, cystitis, arthralgia, and nasopharyngitis. [1][4] PROLIA® is contraindicated in patients with hypocalcemia, pregnancy, or known hypersensitivity to denosumab. A routine oral examination should be completed before treatment, with dental assessment considered for patients with risk factors for osteonecrosis of the jaw. [1]

PROLIA® vs Alternatives—and the JUBBONTI® Biosimilar

• XGEVA®: Contains the same active ingredient, denosumab, but at a different dose and for different indications. PROLIA® is administered at 60mg every six months for osteoporosis and treatment-associated bone loss; XGEVA® is administered at 120mg every four weeks for prevention of skeletal-related events in oncology patients. The two products must not be used concurrently, and practitioners should be clear on this distinction, as confusion between them is a known clinical risk. [1]
• Oral Bisphosphonates: Alendronate, ibandronate, and risedronate remain widely used, lower-cost treatment options. However, their effectiveness in practice can be influenced by missed doses, gastrointestinal side effects, frequent dosing schedules, and strict instructions around fasting and posture. Their use may also be limited in patients with significant renal impairment or certain esophageal disorders. Compared with oral bisphosphonates, denosumab has demonstrated greater gains in bone mineral density and offers a different adherence profile through twice-yearly administration.[6]
• Zoledronic Acid: Once-yearly intravenous administration removes the day-to-day adherence demands of oral therapy. Because zoledronic acid is cleared through the kidneys, renal function is an important factor in patient selection. PROLIA® does not require dose adjustment for renal impairment, although patients with advanced chronic kidney disease remain at increased risk of severe hypocalcemia.[1]
• EVENITY®: Combines anabolic and antiresorptive activity and is administered monthly for up to 12 doses. EVENITY® (romosozumab) may be considered for selected postmenopausal patients at very high fracture risk but carries an FDA Boxed Warning for myocardial infarction, stroke, and cardiovascular death.
• JUBBONTI®: Approved by the FDA in March 2024, JUBBONTI® (denomusab biosimilar) was the first interchangeable biosimilar to PROLIA®. This denosumab biosimilar is supplied as a 60mg/mL prefilled syringe and carries the same approved indications, six-month dosing schedule, and Boxed Warning as the reference product. Phase III biosimilar studies have reported comparable efficacy and safety between denosumab biosimilars and reference denosumab.[2][7]

About PROLIA® and Amgen

PROLIA® is manufactured by Amgen Inc. Denosumab was the first RANKL inhibitor approved for the treatment of osteoporosis. The FDA initially approved PROLIA® on June 1, 2010, for postmenopausal women with osteoporosis at high risk for fracture; indications were subsequently expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with androgen-deprivation or aromatase-inhibitor therapy. [1] PROLIA® is supplied as a single-dose prefilled syringe containing 60mg denosumab in 1mL of solution. Cold-chain integrity from storage to administration is a relevant clinical and sourcing consideration. [1]

PROLIA® Regulatory Status

The FDA approved PROLIA® on June 1, 2010. In January 2024, the agency updated the labeling to add a Boxed Warning for severe hypocalcemia in patients with advanced CKD, including dialysis patients. [1][5] The denosumab market expanded in March 2024 when the FDA approved JUBBONTI® as the first interchangeable biosimilar to PROLIA®. [2]

FAQs

How often is PROLIA® administered?

PROLIA® is given as a 60mg subcutaneous injection once every six months, with adequate calcium and vitamin D supplementation throughout treatment. [1]

What is the Boxed Warning for PROLIA®?

The Boxed Warning addresses severe hypocalcemia in patients with advanced chronic kidney disease, including those on dialysis. Pre-existing hypocalcemia must be corrected before initiating treatment, and calcium should be monitored frequently, particularly during the first 2 to 10 weeks after each administration in this population. [1][5]

What happens if a patient stops PROLIA®?

Discontinuation is associated with rapid rebound bone turnover and an elevated risk of multiple vertebral fractures. Patients stopping PROLIA® must transition to another antiresorptive agent. [1][4]

What is the difference between PROLIA® and XGEVA®?

Both contain denosumab but differ in dose and indication. PROLIA® is 60mg every six months for osteoporosis-related indications; XGEVA® is 120mg every four weeks for oncology skeletal indications. Patients must not receive both concurrently. [1]

Is there a biosimilar to PROLIA®?

Yes — JUBBONTI® (denosumab-bbdz, Sandoz) was FDA-approved in March 2024 as the first interchangeable biosimilar to PROLIA®. [2]

Can PROLIA® be used in patients with renal impairment?

PROLIA® does not require renal dose adjustment and may be considered when bisphosphonate use is limited by renal function. However, patients with advanced CKD face significantly elevated risk of severe hypocalcemia and require careful evaluation and monitoring. [1][5]

How can licensed professionals obtain information about PROLIA®?

Licensed healthcare professionals may contact the Med Supply Solutions support team for general information about PROLIA®.

Citations

[1] U.S. Food and Drug Administration. Prolia® (denosumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s216lbl.pdf [2] U.S. Food and Drug Administration. FDA approves first interchangeable biosimilars to PROLIA® and XGEVA®.  https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and [3] Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493. [4] Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. https://pubmed.ncbi.nlm.nih.gov/19671655/ [5] U.S. Food and Drug Administration. Prolia (denosumab): Drug Safety Communication - FDA Adds Boxed Warning for Increased Risk of Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease. Published January 19, 2024.  https://www.fda.gov/safety/medical-product-safety-information/prolia-denosumab-drug-safety-communication-fda-adds-boxed-warning-increased-risk-severe-hypocalcemia [6] Silva-Fernández L, Rosario MP, Martínez-López JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin. 2013;9(1):42-52. doi:10.1016/j.reuma.2012.06.007 [7] Chung YS, Langdahl B, Plebanski R, et al. SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. Bone. 2025;192:117371. doi:10.1016/j.bone.2024.117371 For licensed healthcare professionals only. The content of this page is provided for informational purposes and does not constitute medical advice.